2022
DOI: 10.1007/s12185-022-03335-7
|View full text |Cite
|
Sign up to set email alerts
|

Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
12
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 21 publications
(12 citation statements)
references
References 146 publications
0
12
0
Order By: Relevance
“…Treatment for PMF was largely supportive in the past [ 7 ] before the emergence of Janus kinase 2 (JAK2) inhibitors, which substantially improved the overall outcomes in these patients, as demonstrated by spleen volume reduction, disease-related symptom improvement, and improved OS observed in clinical trials [ 8 ]. Ruxolitinib is an oral selective inhibitor for JAK1 and JAK2 that showed improved OS in patients with intermediate- or high-risk MF in the COMFORT-I and –II phase 3 trials [ 9 11 ].…”
Section: Introductionmentioning
confidence: 99%
“…Treatment for PMF was largely supportive in the past [ 7 ] before the emergence of Janus kinase 2 (JAK2) inhibitors, which substantially improved the overall outcomes in these patients, as demonstrated by spleen volume reduction, disease-related symptom improvement, and improved OS observed in clinical trials [ 8 ]. Ruxolitinib is an oral selective inhibitor for JAK1 and JAK2 that showed improved OS in patients with intermediate- or high-risk MF in the COMFORT-I and –II phase 3 trials [ 9 11 ].…”
Section: Introductionmentioning
confidence: 99%
“…The treatment was also well tolerated, which was consistent with reports involving ruxolitinib in other clinical settings. 23 No new SAEs were reported.…”
Section: Discussionmentioning
confidence: 99%
“…30 Novel JAKis (pacritinib, momelotinib), and other novel agents (e.g., luspatercept) are being investigated, either alone or in combination, to assess anemia improvement in MF as a primary or secondary aim, because this is one of the most urgent unmet medical needs in the clinical management of patients with MPN. 65 Results from REFINE (cohort 1a; relapsed/refractory MF) demonstrated that hemoglobin levels were stable across the followup period. Of those patients who had hemoglobin levels <10 g/dL at baseline (n = 11), 64% had improvement in hemoglobin of ≥2 g/dL, and one patient who was transfusion-dependent at baseline achieved transfusion independence (n = 1 of 2).…”
Section: Anemia Response In Mfmentioning
confidence: 98%
“…A clinically relevant improvement in anemia is further evidence of possible disease modification with navitoclax plus ruxolitinib treatment or navitoclax alone 30 . Novel JAKis (pacritinib, momelotinib), and other novel agents (e.g., luspatercept) are being investigated, either alone or in combination, to assess anemia improvement in MF as a primary or secondary aim, because this is one of the most urgent unmet medical needs in the clinical management of patients with MPN 65 …”
Section: Evidence Of Disease Modificationmentioning
confidence: 99%